Phaseline

Companies › Precision Biologics

Precision Biologics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NEO-201–Phase 1Non Small Cell Lung CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03476681NEO-201Phase 1Non Small Cell Lung CancerOncologyNov 2026

From the company's SEC filings

Cash and short-term investments of $82m on 2026-09-30; operating cash outflow about $54m a year; runway about 18 months at that burn, to Apr 2028

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.